Do I Qualify for Wegovy in Ireland? BMI Criteria, Costs & Eligibility Explained (2026)

All medical information is reviewed by our clinical partners at MedicOnline.

Dr. Jahan Khan, CMO @ MedicOnline

IMC 409788

Wegovy (semaglutide 2.4 mg) has quickly become one of the most talked-about weight management treatments in Ireland. As a prescription-only medication approved by the European Medicines Agency (EMA), it is not available to everyone - and understanding who qualifies, what it costs, and how it differs from similar medications is essential before you start the process.

This guide covers everything you need to know about Wegovy eligibility in Ireland in 2026: the clinical BMI thresholds, qualifying health conditions, contraindications, the dose schedule, the honest reality of costs, and how it compares to Ozempic - the medication it is most frequently confused with.

The Core Eligibility Criteria: BMI Thresholds

Eligibility for Wegovy is primarily determined by your Body Mass Index (BMI). According to current EMA guidelines and Irish clinical practice, adults must meet one of the following two baseline criteria:

• A BMI of 30 kg/m² or greater (clinically classified as obesity). If you meet this threshold, you do not need any additional weight-related health conditions to be considered.
• A BMI of at least 27 kg/m² but less than 30 kg/m² (classified as overweight), combined with at least one weight-related health condition (see below).

Check your BMI in seconds

Am I eligible for weight loss treatment?

Calculate your BMI to see where your weight loss journey could take you

Metric (kg/cm)Imperial (lbs/ft)

Weight (kg)

Height (cm)

Check Your Eligibility

What Counts as a Weight-Related Health Condition?

If your BMI falls between 27 and 29.9, our clinical partners will review your medical history to determine whether you have a qualifying comorbidity. The officially recognised conditions include:

• Dysglycaemia - covering prediabetes or type 2 diabetes mellitus
• Hypertension - high blood pressure
• Dyslipidaemia - abnormal blood fat levels, such as high cholesterol
• Obstructive sleep apnoea - breathing problems during sleep
• Cardiovascular disease - including a history of heart attack, stroke, or peripheral vascular disease

You do not need to have all of these conditions - a single confirmed diagnosis alongside a BMI of 27-29.9 is generally sufficient for a prescriber to consider Wegovy as a treatment option.

Who Cannot Get Wegovy? Contraindications to Know

Understanding who does not qualify is just as important as knowing who does. Even if you meet the BMI criteria, Wegovy may not be suitable for you if any of the following apply:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• History of pancreatitis - Wegovy is not recommended if you have had acute or chronic pancreatitis
• Pregnancy or breastfeeding - semaglutide should not be used during pregnancy
• Severe renal or hepatic impairment - your prescriber will assess this as part of the clinical review
• Known hypersensitivity to semaglutide or any excipients in the formulation
• Concurrent use of other GLP-1 receptor agonists

Wegovy vs Ozempic: What's the Difference?

This is one of the most common questions we receive, and the confusion is understandable - both medications contain the same active ingredient, semaglutide. However, they are distinct products with different licensed uses, doses, and clinical applications.

The key practical point for Irish patients: Wegovy is the only semaglutide product that is formally licensed for weight management. Ozempic is licensed for type 2 diabetes. Using Ozempic for weight loss is off-label prescribing - but it is Wegovy that is supported by the dedicated weight management trial data (the STEP programme) and the full 2.4 mg dose.

What Does Wegovy Cost in Ireland in 2026?

Cost is the question most patients want answered, and we believe in being upfront about it.

As of 2026, Wegovy is not reimbursed under the General Medical Services (GMS) scheme or the Drug Payment Scheme (DPS) in Ireland. The National Centre for Pharmacoeconomics (NCPE) conducted a health technology assessment, but reimbursement was not approved, meaning patients pay privately.

Typical out-of-pocket costs in Ireland are approximately EUR200-EUR350 per month, depending on the dose (the dose escalates over the first 16 weeks, so costs may vary during that period). This does not include the cost of your online medical consultation, which varies by provider.

The Dose Escalation Schedule

Wegovy is not started at its full maintenance dose. The 16-week titration schedule below is designed to minimise gastrointestinal side effects (nausea, vomiting, diarrhoea) as your body adjusts to the medication:

If side effects are significant at any stage, the prescribing clinician may advise you to remain at a lower dose for longer before stepping up. The goal is always to reach the 2.4 mg maintenance dose, but tolerability takes priority.

What Happens If You Stop Taking Wegovy?

Data from the STEP 1 trial showed that participants who discontinued semaglutide after 68 weeks regained approximately two-thirds of their lost weight within a year of stopping. Weight regain is a recognised and well-documented outcome.

This does not mean Wegovy is ineffective - it means it works in a way similar to blood pressure or cholesterol medication: it manages a condition while you take it. The clinical community increasingly views obesity as a chronic condition that may require long-term or indefinite pharmacological support for many patients.

The Importance of Lifestyle Alongside Wegovy

Wegovy is indicated specifically as an adjunct to a reduced-calorie diet and increased physical activity - not as a standalone treatment. The active substance, semaglutide, works by mimicking the GLP-1 hormone, which regulates appetite by increasing feelings of fullness and reducing hunger and cravings. It makes dietary change more achievable, but it does not replace it.

Patients who achieve the best outcomes typically combine Wegovy with:

• A structured, sustainable reduction in caloric intake (rather than a crash diet)
• Regular physical activity appropriate to their current fitness level
• Ongoing engagement with their clinical team to monitor progress and adjust the plan

Our clinical partners provide dietary and lifestyle guidance as part of the treatment programme, not as an optional add-on.

Wegovy and the Irish Obesity Context

Ireland has one of the highest rates of overweight and obesity in Europe. According to Healthy Ireland survey data, over 60% of Irish adults are living with overweight or obesity - a figure that has increased steadily over the past decade. Weight-related conditions, including type 2 diabetes, cardiovascular disease, and obstructive sleep apnoea, place significant pressure on both individuals and the public health system.

Access to evidence-based medical weight management in Ireland has historically been limited, with long waiting lists for HSE obesity services and limited reimbursement for pharmacological treatment. Telehealth services like ours are increasingly filling that gap - providing convenient, clinically governed access to treatments like Wegovy for patients who meet the appropriate criteria.

Start Your Weight Loss Assessment With Bua Health

Our process is fully digital and can be completed from anywhere in Ireland. Here is what to expect:

If you do not meet the criteria, the clinical team will explain why and may suggest alternative approaches. You'll also receive a full refund if you've paid anything in advance.

References

• 1. European Medicines Agency (EMA). Wegovy (semaglutide) Summary of Product Characteristics.
• 2. National Centre for Pharmacoeconomics (NCPE). Semaglutide (Wegovy(R)) HTA ID: 22029.
• 3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021.
• 4. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA, 2021.
• 5. Healthy Ireland Survey. Department of Health, Ireland. Annual findings on overweight and obesity prevalence.
• 6. Houses of the Oireachtas. Medicinal Products - Parliamentary Questions on Wegovy reimbursement.

Note: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified clinician before beginning any prescription medication.

Related Blogs

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read